Loading...
Knight Therapeutics Inc.
KHTRF•PNK
Healthcare
Drug Manufacturers - Specialty & Generic
$4.22
$-0.19(-4.31%)
Knight Therapeutics Inc. (KHTRF) Financial Performance & Statements
Review Knight Therapeutics Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
13.13%
↑ 13.13%
Operating Income Growth
355.95%
↑ 355.95%
Net Income Growth
125.73%
↑ 125.73%
Operating Cash Flow Growth
0.95%
↑ 0.95%
Operating Margin
-0.21%
↓ 0.21%
Gross Margin
41.82%
↑ 41.82%
Net Profit Margin
2.97%
↑ 2.97%
ROE
1.42%
↑ 1.42%
ROIC
-0.09%
↓ 0.09%
Knight Therapeutics Inc. (KHTRF) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for Knight Therapeutics Inc. stock.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Net Income | $10.73M | $85000.00 | -$1.94M | -$4.55M |
| Depreciation & Amortization | $13.97M | $13.39M | $13.17M | $12.58M |
| Deferred Income Tax | $953000.00 | -$1.34M | $1.41M | -$4.27M |
| Stock Based Compensation | -$502000.00 | $801000.00 | $1.05M | $510000.00 |
| Change In Working Capital | -$12.21M | -$10.99M | -$11.93M | $15.51M |
| Accounts Receivables | -$3.38M | -$9.19M | $998000.00 | $1.28M |
| Inventory | $5.19M | -$9.64M | -$5.66M | $4.19M |
| Accounts Payables | -$9.47M | $9.42M | -$8.70M | $9.38M |
| Other Working Capital | -$4.55M | -$1.58M | $1.42M | $657000.00 |
| Other Non-Cash Items | -$11.48M | $3.07M | -$2.84M | $21.59M |
| Net Cash From Operating Activities | $1.47M | $5.02M | -$1.09M | $30.56M |
| Investments In Property Plant & Equipment | -$560000.00 | -$374000.00 | -$688000.00 | -$10.99M |
| Acquisitions Net | $0.00 | $0.00 | $3000.00 | $58000.00 |
| Purchases Of Investments | -$36.66M | -$46.79M | -$42.70M | -$36.43M |
| Sales/Maturities Of Investments | $55.68M | $60.36M | $69.67M | $22.32M |
| Other Investing Activities | -$415000.00 | -$1.67M | -$16.73M | $97000.00 |
| Net Cash Used For Investing Activities | $18.05M | $11.53M | $9.56M | -$24.95M |
| Debt Repayment | -$7.42M | -$1.40M | -$7.17M | -$2.07M |
| Common Stock Issued | $0.00 | $0.00 | $0.00 | $74000.00 |
| Common Stock Repurchased | -$5.15M | -$2.47M | -$1.24M | $0.00 |
| Dividends Paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Other Financing Activities | -$2.78M | -$55000.00 | -$2.96M | -$905000.00 |
| Net Cash From Financing Activities | -$15.35M | -$3.93M | -$11.36M | -$1.99M |
| Effect Of Forex Changes On Cash | $2.19M | $332000.00 | -$1.33M | $456000.00 |
| Net Change In Cash | $6.35M | $12.95M | -$2.03M | $4.07M |
| Cash At End Of Period | $80.11M | $73.75M | $60.81M | $62.84M |
| Cash At Beginning Of Period | $73.75M | $60.81M | $62.84M | $58.76M |
| Operating Cash Flow | $1.47M | $5.02M | -$2.19M | $30.56M |
| Capital Expenditure | -$1.07M | -$2.04M | -$17.42M | -$10.99M |
| Free Cash Flow | $394000.00 | $2.97M | -$18.51M | $19.57M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan